[go: up one dir, main page]

AR018892A1 - Compuestos de aminotiazol carbono-sustituidos, utiles como inhibidores de quinasas dependientes de ciclinas y las composiciones farmaceuticas que lascontienen, metodo para el tratamiento de enfermedades proliferativas, inflamacion y artritis - Google Patents

Compuestos de aminotiazol carbono-sustituidos, utiles como inhibidores de quinasas dependientes de ciclinas y las composiciones farmaceuticas que lascontienen, metodo para el tratamiento de enfermedades proliferativas, inflamacion y artritis

Info

Publication number
AR018892A1
AR018892A1 ARP990102939A ARP990102939A AR018892A1 AR 018892 A1 AR018892 A1 AR 018892A1 AR P990102939 A ARP990102939 A AR P990102939A AR P990102939 A ARP990102939 A AR P990102939A AR 018892 A1 AR018892 A1 AR 018892A1
Authority
AR
Argentina
Prior art keywords
heteroaryl
cycloalkyl
alkyl
heterocycloalkylalkyl
cycloalkylalkyl
Prior art date
Application number
ARP990102939A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR018892A1 publication Critical patent/AR018892A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Se revelan compuestos aminotiazol carbono-sustituidos que tienen la formula (I) y las sales de los mismos aceptables farmacéuticamente. Lossustituyentes tienen los siguientes significados: R1 = R2, COR2, CONH2, CONR2R3, COOR3, o SO2R3; R2 = H, alquilo, cicloalquilo, heterocicloalquilo,cicloalquilalquilo, heterocicloalquilalquilo, arilo, heteroarilo, arilalquilo, heteroarilalquilo; R3 = alquilo, cicloalquilo, heterocicloalquilo,cicloalquilalquilo, heterocicloalquilalquilo, arilo, heteroarilo, arilalquilo, heteroarilalquilo; A = formula (II), en donde n = 0, 1, 2; m = 1, 2 perotanto n como m pueden ser 2, y X = O, NR12, S, o un enlace, o formula (III), en donde i, j = 0 o 1, pero no pueden ser ambos 1, e Y = alqueno sustituidoopcionalmente, alquilo, o cualesquiera de 2 átomos de carbono adyacentes de un anillo de cicloalquilo o cicloheteroalquilo de 3-7 átomos; R4 = alquilo,cicloalquilo, heterocicloalquilo, cicloalquilalquilo, heterocicloalquilalquilo, alquiloxicarbonilo, arilo, heteroarilo, arilalquilo, heteroarilalquilo,ariloxicarbonilo, o R9; R5, R6, R7, R8 = independientemente H, alquilo, cicloalquilo, heterocicloalquilo, cicloalquilalquilo, heterocicloalquilalquilo,arilo, heteroarilo, arilalquilo, heteroarilalquilo, halo, o hidroxi, alcoxi, amino NR16R17, tio o alquiltio con la condicion de que solamente uno detales grupos de heteroátomos está unido a cualquier átomo de carbon, o R5 = R6 = oxo, o R7 = R8 = oxo, cuando X = un enlace; R9 = formula (IV), en dondeZ = O, NR13,S; R10, R11 = independientemente H, alquilo, cicloalquilo, heterocicloalquilo, cicloalquilalquilo, heterocicloalquilalquilo, arilo,heteroarilo, arilalquilo, heteroarilalquilo, halo, hidroxi, alcoxi, alquilcarboniloxi, carboxi, alquiloxicarbonilo, amino, NR14R15, carbamoílo, ureido, tio,o alquiltio; R12 = H, alquilo, cicloalquilo, heterocicloalquilo, cicloalquilalquilo, heterocicloalquilalquilo, arilo, heteroarilo, arilalquilo,heteroarilalquilo, R13 = H, alquilo, cicloalquilo, heterocicloalquilo,cicloalquilalquilo, heterocicloalquilalquilo, arilo, heteroarilo, arilalquilo,
ARP990102939A 1998-06-18 1999-06-18 Compuestos de aminotiazol carbono-sustituidos, utiles como inhibidores de quinasas dependientes de ciclinas y las composiciones farmaceuticas que lascontienen, metodo para el tratamiento de enfermedades proliferativas, inflamacion y artritis AR018892A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8974798P 1998-06-18 1998-06-18

Publications (1)

Publication Number Publication Date
AR018892A1 true AR018892A1 (es) 2001-12-12

Family

ID=22219395

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102939A AR018892A1 (es) 1998-06-18 1999-06-18 Compuestos de aminotiazol carbono-sustituidos, utiles como inhibidores de quinasas dependientes de ciclinas y las composiciones farmaceuticas que lascontienen, metodo para el tratamiento de enfermedades proliferativas, inflamacion y artritis

Country Status (9)

Country Link
EP (1) EP1087951B9 (es)
JP (1) JP2002518380A (es)
AR (1) AR018892A1 (es)
AT (1) ATE288904T1 (es)
AU (1) AU768751B2 (es)
CA (1) CA2332325A1 (es)
DE (1) DE69923681T2 (es)
ES (1) ES2237919T4 (es)
WO (1) WO1999065884A1 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
WO2000035455A1 (en) * 1998-12-15 2000-06-22 Telik, Inc. Heteroaryl-aryl ureas as igf-1 receptor antagonists
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
JP2001106673A (ja) * 1999-07-26 2001-04-17 Banyu Pharmaceut Co Ltd ビアリールウレア誘導体
US6958333B1 (en) 1999-07-26 2005-10-25 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
CA2384101A1 (en) 1999-09-10 2001-03-15 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001056567A1 (en) * 2000-02-04 2001-08-09 Novo Nordisk A/S 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors
BR0110302A (pt) 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
AU2001252562A1 (en) * 2000-04-28 2001-11-12 Toshiharu Suzuki Medicinal compositions for suppressing beta-amyloid production
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
AU2001259704A1 (en) * 2000-07-26 2002-02-13 Bristol-Myers Squibb Company N-(5-(((5-alkyl-2-oxazolyl)methyl)thio)-2-thiazolyl) carboxamide inhibitors of cyclin dependent kinases
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
DK1347971T3 (da) 2000-12-21 2006-05-15 Bristol Myers Squibb Co Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
ATE509014T1 (de) 2001-01-26 2011-05-15 Chugai Pharmaceutical Co Ltd Malonyl coa-decarboxylase inhibitoren als stoffwechselmodulatoren
US7709510B2 (en) 2001-02-20 2010-05-04 Chugai Seiyaku Kabushiki Kaisha Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
KR100659427B1 (ko) 2001-02-20 2006-12-18 추가이 세이야쿠 가부시키가이샤 대사조절인자로서 유용한 말로닐-코에이 데카르복실라제억제제로서의 아졸류
DE60208630T2 (de) * 2001-05-11 2006-08-17 Pfizer Products Inc., Groton Thiazolderivate und ihre Verwendung als cdk-Inhibitoren
EP1404672B1 (en) 2001-06-22 2006-01-18 Merck & Co., Inc. Tyrosine kinase inhibitors
DE10133665A1 (de) * 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
EP1724270A3 (en) 2001-07-19 2007-01-03 Pfizer Italia S.r.l. Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
RS44304A (sr) 2001-11-22 2007-06-04 Biovitrum Ab., Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1
US7582670B2 (en) 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
US20100098702A1 (en) 2008-09-16 2010-04-22 Longgui Wang Method of treating androgen independent prostate cancer
US8748475B2 (en) 2004-01-12 2014-06-10 Natrogen Therapeutics International, Inc. Methods and compositions for treating lupus
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
DK1483251T3 (da) 2002-03-12 2010-04-12 Bristol Myers Squibb Co C3-cyano-epothilon-derivater
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
FR2850380B1 (fr) * 2003-01-23 2006-07-07 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
US7696365B2 (en) 2003-08-01 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors
DE602004009582T2 (de) 2003-08-01 2009-01-02 Chugai Seiyaku K.K. Cyanoamid-verbindungen als nützliche malonyl-coa decarboxylase-hemmer
EP1653957B1 (en) 2003-08-01 2008-07-09 Chugai Seiyaku Kabushiki Kaisha Piperidine compounds useful as malonyl-coa decarboxylase inhibitors
ATE536872T1 (de) 2003-08-01 2011-12-15 Chugai Pharmaceutical Co Ltd Azol-verbindungen auf cyanoguanidin-basis als malonyl-coa decarboxylase-hemmer
MXPA06001742A (es) * 2003-08-13 2006-08-11 Bf Res Inst Inc Sondas para enfermedades en las cuales se acumula amiloide, agentes para tincion del amiloide, farmacos para tratamiento y profilaxis de enfermedades con amiloide acumulado, y sondas para diagnostico de ovillos neurofibrilares y agentes para tincion
EP1555264A1 (en) * 2004-01-15 2005-07-20 Sireen AG Five-membered heterocyclic compounds as inhibitors of SRC family protein kinase.
WO2006002829A1 (en) * 2004-07-01 2006-01-12 F. Hoffmann-La Roche Ag Thiazolinone unsubstituted quinolines
DE602005024274D1 (de) 2004-07-16 2010-12-02 Sunesis Pharmaceuticals Inc Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
EP1968596A4 (en) * 2005-12-22 2010-12-01 Icagen Inc ANTAGONISTS OF CALCIUM CHANNEL
EA200801716A1 (ru) 2006-01-18 2009-04-28 Амген Инк. Тиазольные соединения и их применение
US20080015193A1 (en) * 2006-06-20 2008-01-17 Mendoza Jose S Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof
JPWO2008050600A1 (ja) * 2006-10-25 2010-02-25 株式会社ニュージェン・ファーマ 酸化ストレス性細胞死を分子背景とする難治性疾患の治療または予防剤
DE602008004769D1 (en) * 2007-05-11 2011-03-10 Hoffmann La Roche Hetarylaniline als modulatoren für amyloid beta
US8541593B2 (en) 2007-06-21 2013-09-24 Amgen Inc. Process for making substituted 2-amino-thiazolones
WO2009011871A2 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
WO2009080694A1 (en) 2007-12-20 2009-07-02 Novartis Ag Thiazole derivatives used as pi 3 kinase inhibitors
CA2705411A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
CN101910142B (zh) 2008-01-11 2013-07-10 弗·哈夫曼-拉罗切有限公司 β-淀粉状蛋白的调节剂
CN101952275B (zh) 2008-02-22 2014-06-18 弗·哈夫曼-拉罗切有限公司 β-淀粉样蛋白的调节剂
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
JP5502089B2 (ja) 2008-10-09 2014-05-28 エフ．ホフマン−ラ ロシュ アーゲー アミロイドβのモジュレーター
JP5378532B2 (ja) 2008-11-10 2013-12-25 エフ．ホフマン−ラ ロシュ アーゲー 複素環γ−セクレターゼモジュレーター
WO2010087315A1 (ja) * 2009-01-29 2010-08-05 株式会社林原生物化学研究所 抗アルツハイマー病剤
US20120035187A1 (en) * 2009-01-29 2012-02-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Anti-neurodegenerative disease agent
JPWO2010087313A1 (ja) * 2009-01-29 2012-08-02 株式会社林原生物化学研究所 神経突起伸展促進剤
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
EP2922832B1 (en) 2012-11-21 2019-10-09 Agios Pharmaceuticals, Inc. Glutaminase inhibitors and methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
BR112016021620A2 (pt) 2014-03-21 2018-07-10 Agios Pharmaceuticals Inc compostos e seus métodos de uso
WO2017027984A1 (en) * 2015-08-20 2017-02-23 Simon Fraser University Compounds and methods for treatment of cancer by inhibiting atg4b and blocking autophagy
CN112739695B (zh) 2018-09-17 2025-03-18 永进药品工业株式会社 新型噻唑衍生物及其药学上可接受的盐

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3169954A (en) * 1962-08-06 1965-02-16 Eastman Kodak Co Monoazo thiazole dyestuffs
DE3418376A1 (de) * 1984-05-17 1985-11-21 Bayer Ag, 5090 Leverkusen Zwischenprodukte sowie verfahren zur herstellung von zwischenprodukten fuer die synthese von cephalosporinen
FR2612187B1 (fr) * 1987-03-12 1989-07-21 Sanofi Sa Derives du thiazole actifs sur le systeme cholinergique, leur procede de preparation et compositions pharmaceutiques en contenant
TW513418B (en) * 1996-07-31 2002-12-11 Otsuka Pharma Co Ltd Thiazole derivatives, their production and use
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
GB9823873D0 (en) * 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents

Also Published As

Publication number Publication date
DE69923681D1 (de) 2005-03-17
ATE288904T1 (de) 2005-02-15
EP1087951B9 (en) 2006-09-13
WO1999065884A1 (en) 1999-12-23
ES2237919T3 (es) 2005-08-01
DE69923681T2 (de) 2006-01-12
EP1087951A1 (en) 2001-04-04
EP1087951B1 (en) 2005-02-09
EP1087951A4 (en) 2002-08-14
AU768751B2 (en) 2004-01-08
AU4431199A (en) 2000-01-05
CA2332325A1 (en) 1999-12-23
JP2002518380A (ja) 2002-06-25
ES2237919T4 (es) 2007-05-01

Similar Documents

Publication Publication Date Title
AR018892A1 (es) Compuestos de aminotiazol carbono-sustituidos, utiles como inhibidores de quinasas dependientes de ciclinas y las composiciones farmaceuticas que lascontienen, metodo para el tratamiento de enfermedades proliferativas, inflamacion y artritis
MX9404749A (es) Heterociclos de fenilo como inhibidores de cox-2.
CY1108445T1 (el) Νεα μεθοδος συνθεσης και νεα κρυσταλλικη μορφη της αγομελατινης καθως και φαρμακευτικες συνθεσεις που την περιεχουν
UY27918A1 (es) Derivados de benzodioxol
AR017182A1 (es) Compuestos de aminotiazol, inhibidores de las kinasas dependientes de ciclinas y las composiciones farmaceuticas que los contienen.
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
TW200526658A (en) Heterocyclic inhibitors of MEK and methods of use thereof
AR044543A1 (es) Derivados de pirazolo-quinazolina, un procedimiento para su preparacion y su uso como inhibidor de quinasa
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
YU18999A (sh) Supstituisani tricikli
BRPI0418031A (pt) inibidores de quinase fosfonato-substituìdos
TW200716531A (en) Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia
ATE374773T1 (de) Polycyclische verbindungen als potenten alpha2- adrenoceptor antagonisten
BG104287A (en) Halogensubstituted tetracyclic derivatives of tetrahydrofuran
BR0207846A (pt) Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas
DK1483251T3 (da) C3-cyano-epothilon-derivater
PE20050336A1 (es) Compuestos triciclicos como inhibidores de la proteina farnesil transferasa
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
DE602005022284D1 (de) Substituierte benzimidazole und deren verwendung zur induktion von apoptose
AR054707A1 (es) Derivados de octahidropirrolo 3,4-c pirrol, un procedimiento para su preparacion, una composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento
AR027035A1 (es) Pirroles sustituidos
ECSP993012A (es) Inhibidores de aminotiazol substituidos con carbon de cianasa dependientes de la ciclina
DK1072601T3 (da) 4-Arylpiperidinderivater til behandling af pruritus
ES2183500T3 (es) Nuevos compuestos y composiciones farmaceuticas que los contienen.
TW200621227A (en) Medicament for preventing or treating fatty liver